Orphazyme20.jpg

Outlook

Outlook

The Company expects a net loss for 2018 of DKK 245 - 275 million. The outlook range reflects the inherent uncertainty related to the timing of patient enrollment and similar operational uncertainties. The two most relevant cost drivers affecting the outlook are the progress in patient enrollment in the sIBM trial and the planned ALS trial. Orphazyme’s result of operations for 2018 could deviate materially from this forecast.